On January 7, 2021 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present in a fireside chat at the H.C. Wainwright BioConnect Conference being held virtually on January 11-14, 2021 (Press release, NicOx, JAN 7, 2021, https://www.nicox.com/news-media/nicox-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference/ [SID1234573630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of Nicox’s presentation will be available on-demand from Monday January 11 at 6:00 a.m. EST for one week by clicking here and accessible on Nicox’s website (www.nicox.com) in the "Presentations & Events" section. The video webcast will be available for 90 days.

On January 7, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for all three investor conferences are as follows:

39th Annual J.P. Morgan Healthcare Conference – Corporate Presentation

Date:

January 14, 2021

Time:

2:00 p.m. ET

Webcast:

Audio-only Link to Webcast Here

2021 LifeSci Advisors – Corporate Access Event

Date:

January 7-13, 2021

Time:

Management available for 1×1 meetings

H.C. Wainwright BioConnect 2021 Conference – Corporate Presentation

Date:

January 11-14, 2021

The session time is on-demand, beginning Monday January 11 starting 6:00 a.m. ET.

To register and view the presentation, please click here.

A replay for all conferences will be available on the Events and Presentations section investor section of the Infinity Pharmaceuticals website View Source following the conference.

On January 7, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference (Press release, Zymeworks, JAN 7, 2021, View Source [SID1234573628]). In addition, Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49’s clinical progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Healthcare Conference Presentation

The J.P. Morgan presentation will take place on Monday, January 11, 2021 at 3:40 p.m. ET.

Zanidatamab ASCO (Free ASCO Whitepaper) GI Webcast

Zymeworks will host a webcast on Friday, January 15, 2021 at 5:00 pm ET to discuss the clinical results for the Company’s HER2 bispecific, zanidatamab, in biliary tract cancer and gastroesophageal cancer presented at ASCO (Free ASCO Whitepaper) GI earlier that day. The data will be discussed by lead investigator, Dr. Funda Meric-Bernstam, M.D., Clinical Investigator and Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

ZW49 Clinical Update Webcast

Zymeworks will host a webcast on Wednesday, January 27, 2021 at 4:30 pm ET to provide an update on clinical progress from the Phase 1 dose-escalation study for the Company’s HER2 bispecific antibody-drug conjugate, ZW49.

Interested parties can access these live webcasts via a link from Zymeworks’ website at View Source Participants are encouraged to connect five to ten minutes prior to the scheduled start time. A recorded replay will also be available on the website shortly after the webcast concludes.

On January 7, 2021 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows (Press release, Syros Pharmaceuticals, JAN 7, 2021, View Source [SID1234573627]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

39th Annual J.P. Morgan Healthcare Conference:
Date: Thursday, January 14
Time: 2:50 p.m. ET

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

On January 7, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 14th at 11:40 a.m. ET (Press release, CytomX Therapeutics, JAN 7, 2021, View Source [SID1234573626]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CytomX Therapeutics will also participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event taking place from January 11-14, 2021.

Webcast from the conference and corporate access event will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay of the conference presentation will be available for 90 days following the conference. A recording of the corporate access presentation will also be available for 30 days following the event.